Summary:
Click image to enlargeA Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention (see ad)
Criteria:- Age of onset of migraines prior to 50 years of age
- Migraine attacks, on average, lasting 4 - 72 hours if untreated
- Per subject report, 4 - 18 migraine attacks of moderate to severe intensity per month within the last 3 months prior to the Screening Visit
- Six or more migraine days during the Observation Period
- Not more than 18 headache days during the Observation Period
- Ability to distinguish migraine attacks from tension/cluster headaches
- Subjects on prophylactic migraine medication are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the Screening Visit, and the dose is not expected to change during the course of the study.
Qualified Participants May Receive:
Up to $1000 for time and travel